BofA raised the firm’s price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced a favorable Caplyta patent settlement with Sandoz ...

Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

Investment analysts at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) ...

Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold ... rating of “Moderate Buy” and a consensus price target of $103.62. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This ...

Canaccord downgraded Intra-Cellular (ITCI) to Hold from Buy with a price target of $132, up from $119, after Johnson & Johnson (JNJ) agreed ...

Observing a 9.56% increase, the current average has risen from the previous average price target of $99.33. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Intra-Cellular ...

Intra-Cellular said last fall it was expanding its sales force to target growth opportunities with primary care doctors. The company also is seeking U.S. Food and Drug Administration approval to ...

RBC did slightly trim its target due to broader market jitters, but that hasn't dulled the excitement. Founded on Nobel Prize-winning research, Intra-Cellular Therapies is proving it's not just ...